Literature DB >> 27134915

A Fatal Case of Acute Myeloid Leukaemia-Methotrexate Related or Primary Autoimmune Disease Related: A Rare Case Report.

Saurabh Agarwal1, Nidhi Kaeley1, Priyanka Gupta2, Vibha Gupta3, Rohan Bhatia4.   

Abstract

Methotrexate is being used for many years in the treatment of chronic medical disorders e.g. rheumatoid arthritis since 1951. It has been associated with various systemic toxicities and complications including bone marrow suppression and lymphomas. The development of leukaemia in a patient of chronic rheumatoid arthritis is either related with the primary disease or due to the drugs which are used in the treatment like cyclophosphamide. In our present case, a 70-year-old female who was a known case of Rheumatoid Arthritis (RA) and was on methotrexate once a week orally for the past 20 years presented with complaints of loss of appetite, loss of weight and anaemia since 2 months. After thorough examination and investigation, she was diagnosed with acute myeloid leukaemia (AML-M4) with bilateral chest consolidation.

Entities:  

Keywords:  Bone marrow suppression; Chest consolidation; Rheumatoid arthritis; Systemic toxicities

Year:  2016        PMID: 27134915      PMCID: PMC4843301          DOI: 10.7860/JCDR/2016/16516.7359

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  13 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

Review 2.  Malignancies and soluble tumor antigens in rheumatic diseases.

Authors:  Eva Szekanecz; Csilla András; Zsuzsa Sándor; Péter Antal-Szalmás; János Szántó; László Tamási; Emese Kiss; Zoltán Szekanecz
Journal:  Autoimmun Rev       Date:  2006-04-19       Impact factor: 9.754

Review 3.  Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.

Authors:  Claire Seedhouse; Nigel Russell
Journal:  Br J Haematol       Date:  2007-06       Impact factor: 6.998

Review 4.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

5.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

Authors:  Xavier Mariette; Dominique Cazals-Hatem; Josiane Warszawki; Frédéric Liote; Nathalie Balandraud; Jean Sibilia
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

Review 6.  Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis.

Authors:  Bruce N Cronstein
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

7.  Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.

Authors:  Byung-Ryul Choi; Myung-Ju Ahn; Woong Soo Lee; Tae-Hwan Kim; Sang-Cheol Bae; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2004-08-25       Impact factor: 2.631

Review 8.  [Effect of methotrexate on the immune response in selected experimental models].

Authors:  Michał Zimecki; Jolanta Artym
Journal:  Postepy Hig Med Dosw (Online)       Date:  2004-04-20       Impact factor: 0.270

Review 9.  Therapy-related myeloid leukemia.

Authors:  Lucy A Godley; Richard A Larson
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

10.  Methotrexate-induced acute leukemia: report of three cases and review of the literature.

Authors:  Khalid A Al-Anazi; Khalid I Eltayeb; Mohammed Bakr; Fahad I Al-Mohareb
Journal:  Clin Med Case Rep       Date:  2009-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.